viernes, 4 de julio de 2014

Hipertensión pulmonar crónica tromboembólica/Chronic thromboembolic pulmonary hypertension

Hipertensión pulmonar crónica tromboembólica

Chronic Thromboembolic Pulmonary Hypertension
Peter Fedullo, Kim M. Kerr, Nick H. Kim, and William R. Auger1
Division of Pulmonary and Critical Care Medicine, University of California, San Diego, San Diego, California
Am J Respir Crit Care Med Vol 183. pp 1605-1613, 2011

Hipertensión pulmonar crónica tromboembólica. Manejo médico

Chronic thromboembolic pulmonary hypertension: Medical treatment.
Ozsu S, Cinarka H.
Pulm Circ. 2013 Apr;3(2):341-344.
Chronic thromboembolic pulmonary hypertension (CTEPH) is responsible for significant levels of morbidity and mortality. The estimated cumulative incidence of CTEPH is 2-4% among patients presenting with acute pulmonary thromboembolism. Currently, at the time of CTEPH diagnosis, 37.9% of the patients in an international registry were receiving at least one pulmonary arterial hypertension (PAH)-targeted therapy. Advanced medical therapy is considered in patients with inoperable disease, as a bridge to pulmonary endarterectomy or in those with persistent or recurrent pulmonary hypertension. PAH-specific medical therapies include endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogues. The present article will focus on recent developments in the pharmacological treatment of CTEPH.
KEYWORDS: chronic thromboembolism, medical treatment, pulmonary hypertension

Anestesiología y Medicina del Dolor

Publicar un comentario